Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × NETWORK × Serotonin Syndrome × Clear all

Phase

Status

Sponsor Class

INDUSTRY 3 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 71 Prostatic Neoplasms 42 Lymphoma 29 Multiple Myeloma 27 Squamous Cell Carcinoma of Head and Neck 25 Head and Neck Neoplasms 25 Colorectal Neoplasms 24 Precursor Cell Lymphoblastic Leukemia-Lymphoma 23 Leukemia 23 Carcinoma, Non-Small-Cell Lung 23 Lung Neoplasms 22 Rectal Neoplasms 20 Colonic Neoplasms 19 Neoplasm Metastasis 18 Leukemia, Myeloid, Acute 18 Sarcoma 17 Uterine Cervical Neoplasms 16 Central Nervous System Neoplasms 16 Ovarian Neoplasms 15 Hodgkin Disease 15 Brain Neoplasms 14 Urinary Bladder Neoplasms 11 Lymphoma, Follicular 11 Carcinoma, Ovarian Epithelial 11 Burkitt Lymphoma 11 Astrocytoma 11 Pancreatic Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 10 Fallopian Tube Neoplasms 10 Rhabdomyosarcoma 9

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡